John Libbey Eurotext

European Journal of Dermatology


The burden of chronic urticaria: French baseline data from the international real-life AWARE study Volume 29, numéro 1, January-February 2019


  • Figure 1
  • Figure 2


1 Dermato-Allergology Department, CHRU Poitiers, Poitiers,
2 Dermatology Department, Private Hospital, Antony,
3 Dermatology and Allergology Department, CHU Grenoble, La Tronche,
4 Dermatology office, Compiègne,
5 Dermatology office, Montluçon,
6 Novartis Pharma SAS, Rueil-Malmaison,
7 Dermatology Department, Larrey Hospital, CHU Toulouse, Toulouse, France
* Reprints

Background: The AWARE study is an ongoing international study of patients with chronic urticaria refractory to H1-antihistamines. The aim of this study is to evaluate the burden of disease and the use of healthcare resources in real-life conditions. Objectives: To analyse the baseline data of French patients included in the AWARE study. Materials & Methods: AWARE is a prospective, non-interventional, international study that includes adult patients who have had chronic urticaria, refractory to at least one H1-antihistamine, for at least two months. Results: Ninety-four patients (mean age: 47.9 years; 71.3% women) with chronic urticaria (50.0% spontaneous only, 9.6% inducible only, and 40.4% both) were included in French centres. The median duration from diagnosis was three years and angioedema was present in 31.5% of patients for the past six months. In 63.8% of cases, the patients received at least one treatment for urticaria (H1-antihistamine for 66.0%). Chronic urticaria was poorly controlled (UCT score <12) in 88.9% of patients and quality of life was severely impaired (mean DLQI score: 8.6). The use of healthcare resources was significant with frequent visits to general practitioners (80.8% of patients; mean: 8.1 visits). However, more than half of patients had not previously consulted a dermatologist. Conclusion: These baseline data of French patients in the AWARE study show that patients suffering from chronic urticaria, refractory to H1-antihistamines for a median of three years, are insufficiently treated and that their quality of life is impaired. Despite the significant use of healthcare resources, access to specialised consultations remains insufficient.